"Over the past decade, HCmed has achieved numerous milestones," said Cheng. ""Over the past decade, HCmed has achieved numerous milestones," said Cheng. "We have now become one of the leading CDMOs in drug-nebulizer combination development. HCmed has continuously pushed the boundaries, collaborating with world-class pharmaceutical partners, and earning the trust of prestigious global clients across the United States, Asia and Europe. In 2023, we established our first overseas presence in the United Kingdom, enabling us to provide customization services to an even broader customer base."

HCmed has designated 2024 as the "Branding Year," year in which the company sets its sights on further solidifying its position in the field. With the maturation of our latest second-generation product, AdheResp - the Smart Breath-Actuated Mesh Nebulizer, HCmed is more committed than ever to expanding its reach and introducing its innovative products and services to an even wider audience.

"Looking ahead, we also plan to develop new product lines, with the goal of cementing HCmed's place as a leader in the respiratory care industry," Cheng added.

As HCmed Innovations embarks on this new chapter, the company's unwavering dedication to driving innovation and delivering cutting-edge solutions that improve patient outcomes will continue to be the guiding force behind its success.